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Objectives: To investigate the antistaphylococcal/antibiofilmactivity andmode of action (MOA) of a panel of redox-
active (RA) compounds with a history of human use and to provide a preliminary preclinical assessment of their
potential for topical treatment of staphylococcal infections, including those involving a biofilm component.
Methods: Antistaphylococcal activity was evaluated by brothmicrodilution and by time–kill studies with growing
and slow- or non-growing cells. The antibiofilm activity of RA compounds, alone and in combination with estab-
lished antibacterial agents, was assessed using the Calgary Biofilm Device. Established assays were used to
examine the membrane-perturbing effects of RA compounds, to measure penetration into biofilms and physical
disruption of biofilms and to assess resistance potential. A living skin equivalent model was used to assess the
effects of RA compounds on human skin.
Results: All 15 RA compounds tested displayed antistaphylococcal activity against planktonic cultures
(MIC 0.25–128 mg/L) and 7 eradicated staphylococcal biofilms (minimum biofilm eradication concentration
4–256 mg/L). The MOA of all compounds involved perturbation of the bacterial membrane, whilst selected com-
pounds with antibiofilm activity caused destructuring of the biofilm matrix. The two most promising agents
[celastrol and nordihydroguaiaretic acid (NDGA)] in respect of antibacterial potency and selective toxicity against
bacterialmembranes acted synergistically with gentamicin against biofilms, did not damage artificial skin follow-
ing topical application and exhibited low resistance potential.
Conclusions: In contrast to established antibacterial drugs, some RA compounds are capable of eradicating
staphylococcal biofilms. Of these, celastrol and NDGA represent particularly attractive candidates for develop-
ment as topical antistaphylococcal biofilm treatments.
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Introduction
Biofilms comprise surface-attached microbial communities
encased within a self-produced extracellular matrix and are
found in 80% of bacterial infections in humans.1 Infections
including a biofilm component can be extremely challenging to
treat: not only are biofilms refractory to killing by the majority of
antibacterial drug classes in clinical use, but they also represent a
sanctuary site in which bacteria are physically shielded from
attack by the host immune system.1,2 To address the current dif-
ficulties in treating biofilm infections, it will be important to dis-
cover antibacterial agents capable of demonstrating effective
killing and/or eradication of bacterial biofilms.
In ongoing studies, we have been seeking to identify com-
pounds with the potential for topical treatment of human
skin infections including a biofilm component, such as infected
wounds. Our approach has focused on evaluating the antibiofilm
activity of compounds already in human use for cosmetic or
healthcare applications, or that have been approved for human
consumption, since the repurposing of chemicals with established
safety profiles potentially offers an accelerated route by which
antibiofilm agents can enter into clinical use.We recently reported
that tert-butylhydroquinone (TBHQ), an antioxidant with a history
of safe use as a food preservative, undergoes spontaneous con-
version to tert-butylbenzoquinone (TBBQ), which exhibits potent
activity against staphylococcal biofilms.3 In the present study,
we examined the antistaphylococcal activity of a range of other
redox-active compounds with a history of safe or traditional use
in humans, with an emphasis on assessing their activity against
biofilms and elucidating their antibacterial and antibiofilm
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mode(s) of action. Several of the compounds investigated dis-
played potent activity against staphylococcal biofilms and a sub-
set of these was found to exhibit properties that make them
suitable to be considered for application as topical biofilm treat-
ments. These compounds, or derivatives thereof, may therefore
represent candidates for development as novel therapies for
superficial skin infections.
Materials and methods
Bacterial strains and routine culture
The laboratory strain Staphylococcus aureus SH10004,5 and the prolific
biofilm-forming strains S. aureus UAMS-16 and Staphylococcus epidermidis
RP62A (ATCC 35984)7 were used throughout this study. Bacteria were cul-
tured using Mueller–Hinton broth (MHB) and agar (MHA) (Oxoid,
Cambridge, UK), supplemented with calcium (50 mg/L, in the form of
CaCl2) for studies with daptomycin.
Chemicals and reagents
The compounds used in this study, 2,2′-methylenebis[6-tert-butyl-4-
methylphenol] (AO 2246), bakuchiol, benzoyl peroxide, carnosic acid,
celastrol, dihydroxychalcone, 8-hydroxyquinoline, idebenone, dodecyl
gallate (lauryl gallate), menadione, nordihydroguaiaretic acid (NDGA), thy-
mohydroquinone, thymoquinone, totarol and vitamin K5 hydrochloride,
were gifts from Syntopix Group plc (Bradford, UK) [known latterly as
Evocutis plc (Wetherby, UK)]. Other chemicals and antibiotics were from
Sigma-Aldrich (Poole, UK), with the following exceptions: ampicillin
(Fisher Scientific, Loughborough, UK), cefotaxime (MP Biomedicals,
Illkirch Cedex, France), ciprofloxacin (Bayer, Leverkusen, Germany), dapto-
mycin (Cubist Pharmaceuticals, Lexington, MA, USA), flucloxacillin (CP
Pharmaceuticals, Wrexham, UK), meropenem (AstraZeneca, Wilmington,
DE, USA), vancomycin (Duchefa Biochemie, Haarlem, the Netherlands) and
ethanol (Fisher Scientific). SYPROw Ruby, DiSC3(5) and the Live/Dead
BacLightTM kit were from Invitrogen (Paisley, UK).
Evaluation of antibacterial activity
Antibacterial susceptibility testing with planktonic cultures was performed
by exposing bacteria to serial dilutions of compounds in MHB according to
the broth microdilution guidelines provided by the CLSI.8 Minimum biofilm
eradication concentrations (MBECs) were determined for biofilm cultures
grown using the Calgary Biofilm Device (CBD) (Nunc A/S, Roskilde,
Denmark) and were defined as the lowest concentration of compound
capable of sterilizing the biofilm.9
Synergistic interactions between redox-active compounds and estab-
lished antibacterial drugs were examined against biofilms grown on the
CBD using the chequerboard method, as described previously.10 A frac-
tional inhibitory concentration (FIC) index of ≤0.5 was taken to indicate
a synergistic interaction, whilst values of 1 and ≥2 were taken to indicate
additivity and antagonism, respectively.10
Time–kill experiments with exponential-phase cultures were performed
as described3 using cultures grown to an OD600 of 0.2 (108 cfu/mL). For
time–kill studies with non-growing (stationary phase) bacteria, overnight
(16 h) cultures of S. aureus SH1000 were centrifuged and cells resus-
pended in the spent medium to an OD600 of 0.2 prior to exposure to
antibacterial agents. Persister cells were generated by growing S. aureus
SH1000 to an OD600 of 0.2 and exposing the cells to ampicillin or cipro-
floxacin at 10×MIC for 24 h at 378C. Persisters were washed, resuspended
in the same volume of fresh MHB and challenged with antibacterial com-
pounds at 10×MIC.11,12 Bacterial viability was monitored post-challenge
by plating cultures onto MHA and enumerating colonies after incubation
for 18–24 h at 378C. To detect bacterial lysis following challenge with
redox-active compounds at 4× MIC, the culture turbidity of early
exponential-phase cultures (OD600 of 0.2) at 378C was monitored by
absorbance measurements at 600 nm.13
Antibacterial mode of action (MOA) studies
The effect of 10 min of exposure to antibacterial compounds on the integ-
rity of the staphylococcal membrane was assessed at 4×MIC using the
BacLightTM assay14 and by monitoring leakage of potassium ions from
cells resuspended in 5 mM HEPES-glucose buffer (pH 7.2) after 3 h.15,16
Membrane potential was determined by measuring intracellular and extra-
cellular levels of the fluorescent dye DiSC3(5) following exposure to antibac-
terial agents in HEPES-glucose buffer for 3 h at 4×MIC.15,17 The effect of
compounds on mammalian membranes was examined by monitoring
haemolysis of erythrocytes isolated from lithium heparin-treated whole
equine blood (Matrix Biologicals Ltd, Hull, UK), as previously described.3
Assessing penetration of redox-active compounds into
staphylococcal biofilms
Biofilms were grown on cellulose ester membrane filter discs (Millipore,
Billerica, MA, USA) placed on Brain Heart Infusion Agar (BHIA; Oxoid) for
48 h,7 and the discs were then transferred to BHIA containing redox-active
compounds. A 13 mm cellulose disc (Millipore) was placed on the biofilm,
on top of which was placed a 6 mm filter paper disc (Oxoid) moistened
with PBS. Following incubation at 378C for 24 h, the 6 mm disc was trans-
ferred to MHA spread with SH1000. After incubation at 378C for 24 h, the
diameter of the zone of inhibition around the discwasmeasured and com-
pared with a calibration curve of zones of inhibition generated using discs
impregnated with known concentrations of the test compound.
Percentage penetration of compound into the biofilm was calculated
with respect to a control assembly containing no biofilm.18
Determining the effect of redox-active agents
on biofilm structure and viability
Alterations in biofilm structure following challenge with antibacterial
agents were assessed by quantifying matrix material and adhered cells
by stainingwith SYPROw Rubyand SYTOw 9, respectively.19 Microtitre plates
were pre-conditioned with 20% normal pooled human plasma (Sera
Laboratories International, Haywards Heath, UK) in 0.05 M carbonate buf-
fer overnight at 48C. Wells were seeded with S. aureus SH1000 in Tryptone
Soya Broth (Oxoid) and plates were incubated for 24 h at 378Cwith gentle
shaking to establish biofilms. Biofilms were then challenged with redox-
active compounds at 256 mg/L in MHB or with proteinase K (100 mg/L)
in buffer (20 mM Tris, pH 7.5, and 100 mM NaCl) for 60 min or 24 h.19
Biofilms were washed in water before being stained with undiluted
FilmTracerTM SYPROw Ruby containing 0.17 mM SYTOw 9 for 30 min.
Following a further wash in water, fluorescence was measured at an exci-
tation wavelength of 480 nm and an emission wavelength of 620 nm
(matrix) or 520 nm (cells).19 In parallel experiments, total biofilm viability
was measured following exposure of established biofilms to compounds
for 1 h. Detached cells were collected and adherent cells were dispersed
by incubation with proteinase K (100 mg/L) in buffer for 1 h. All cells
werewashed in PBS before being plated ontoMHA and enumeration of col-
onies was carried out after incubation for 18–24 h at 378C.
Preliminary evaluation of the potential for use
as topical antistaphylococcal agents
To examinewhether redox-active compounds are toxic to human skin, the
effect of compounds on a human living skin equivalent was assessed. Fully
differentiated, 28 day old LabSkinTM (Innovenn, Dublin, Ireland)20 and
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maintenance medium were produced and donated by Evocutis plc. Skin
was exposed to 100 mL of test compound at 10× or 4× MIC in sterile
deionized water (solvent load: 0.2% ethanol, v/v) for 24 h at 378C, 5%
CO2, .95% relative humidity.
20 Drug-free controls were exposed to deio-
nized water or solvent alone and the positive control was incubated with
5% SDS. Following incubation, LabSkinTM medium was sampled and tissue
was fixed in 10% neutral buffered formalin for 24 h. Fixed tissues were
embedded in wax and subjected to haematoxylin/eosin staining and visual
inspection of tissue sections.20 To detect potential skin irritation induced by
application of compounds, IL-1a was measured in medium sampled fol-
lowing 24 h of incubation with compounds.21,22 IL-1a quantification was
performed using a human IL-1a/IL-1F1 Quantikine ELISA Kit (R&D
Systems, Abingdon, UK) according to the manufacturer’s instructions and
compared with the positive control.
The potential for development of resistance to redox-active com-
pounds was assessed by determining mutation frequencies at 4×MIC,7
and selection using the extended gradient MIC method as previously
described.23
Results and discussion
Antistaphylococcal properties of redox-active compounds
Although it has previously been reported that the redox-active
compounds examined in this study possess antibacterial activ-
ity,24–38most have not been evaluated for their antistaphylococcal
activity using standardized procedures for susceptibility testing.
Furthermore, these compounds have not been evaluated for their
ability to eradicate staphylococcal biofilms. Since staphylococci
form biofilms that vary in their matrix composition,7,39,40 suscepti-
bility testing was carried out with three staphylococcal strains (S.
aureus SH1000 and UAMS-1, S. epidermidis RP62A) that form dis-
tinct types of biofilm. Using CLSI methodology, the 15 redox-active
compounds tested exhibited MICs ranging from 0.25 to 128 mg/L
for planktonic cultures of S. aureus and S. epidermidis (Table 1). In
subsequent experiments to assess their antibiofilm activity,
approximately half (7/15) of these compounds demonstrated
complete eradication of preformed staphylococcal biofilms at con-
centrations ≤256 mg/L, in some cases exhibiting MBEC values as
low as 4 mg/L (Table 1). By contrast, none of the established anti-
bacterial agents tested (cefotaxime, chlorhexidine, ciprofloxacin,
cetyltrimethylammoniumbromide, daptomycin, erythromycin, fos-
fomycin, flucloxacillin, fusidic acid, gentamicin,meropenem,mupir-
ocin, oxacillin, rifampicin, SDS, tetracycline and vancomycin) was
able to eradicate SH1000 biofilms at≤256 mg/L (data not shown).
The ability of several of the redox-active compounds to com-
pletely eradicate biofilms suggested that they exert a bactericidal
action. To assess this, we examined compound-mediated killing of
SH1000 in planktonic culture by viable counting. At 4×MIC, the
majority of the compounds (benzoyl peroxide, carnosic acid, dihy-
droxychalcone, 8-hydroxyquinoline, lauryl gallate, menadione,
NDGA, thymoquinone and vitamin K5 hydrochloride) were bacteri-
cidal (Figure 1). At concentrations corresponding to the MBEC,
benzoyl peroxide, carnosic acid, celastrol and NDGA sterilized
planktonic cultures at 24 h (limit of detection of 1 log10 cfu/mL).
AO 2246, bakuchiol and totarol killed bacteria initially, causing
≥2.8 log10 reduction in cfu/mL after 1 h, but allowed grow-back
over a 24 h period (data not shown). Therefore, none of the agents
with antibiofilm activity displayed exclusively bacteriostatic prop-
erties. Bacterial killing was not associated with reductions in cul-
ture turbidity over 24 h, indicating that killing did not result from,
or trigger, cell lysis (data not shown); however, benzoyl peroxide
interfered with absorbance readings at OD600 and was not there-
fore evaluated for its ability to cause bacterial lysis.
MOA of redox-active compounds
The results of previous studies by us and others suggest that the
redox-active compounds TBBQ, bakuchiol and totarol exert their
antibacterial effects through perturbation of the bacterial mem-
brane.3,35,41 We therefore examined whether other redox-active
compounds act in the samemanner. At 4×MIC, 10 of the 15 com-
pounds compromised the integrity of the membrane of S. aureus
Table 1. MICs and MBECs of redox-active compounds for staphylococci
Compound
Strain
SH1000 UAMS-1 RP62A SH1000 UAMS-1 RP62A
MIC (mg/L) MBEC (mg/L)
AO 2246 4 4 4 16 16 128
Bakuchiol 4 4 4 16 8 8
Benzoyl peroxide 64 32 32 256 32 64
Carnosic acid 32 32 8 128 64 64
Celastrol 1 0.5 0.25 32 4 4
Dihydroxychalcone 128 128 128 .256 .256 .256
8-Hydroxyquinoline 4 2 1 .256 32 .256
Idebenone 64 64 32 .256 256 .256
Lauryl gallate 64 64 16 .256 256 .256
Menadione 16 8 8 .256 128 256
NDGA 64 64 64 128 16 256
Thymohydroquinone 16 8 16 .256 16 64
Thymoquinone 16 8 8 .256 4 32
Totarol 4 2 2 16 8 16
Vitamin K5 hydrochloride 32 16 16 .256 64 128
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481
JAC
SH1000 within 10 min, as measured by the BacLightTM assay
(Figure 2a). Since this assay may not reliably detect subtle mem-
brane perturbation (e.g. loss of membrane potential) or perturb-
ation occurring over longer time periods, we employed additional
assays to assess whether the other five compounds also mediate
membrane perturbation. All five caused complete or near-
complete loss of membrane potential within 3 h at 4×MIC, as
measured by reduction in intracellular and increase in extracellu-
lar levels of the membrane-potential sensitive dye DiSC3(5); fur-
thermore, some of these agents (e.g. thymoquinone) prompted
leakage of intracellular potassium over this duration and at this
concentration (Figure 2b and c). Thus, all of the redox-active com-
pounds tested caused membrane perturbation, albeit at different
rates and to different extents.
To establish whether the redox-active compounds display spe-
cificity for the bacterial membrane, we challenged mammalian
erythrocytes with compounds at a concentration equivalent to
4×MIC for S. aureus SH1000 andmonitored haemoglobin leakage
over 1 h. Of the 15 agents tested, 6 (celastrol, 8-hydroxyquinoline,
menadione, NDGA, thymohydroquinone and thymoquinone) did
not induce substantial haemolysis (Figure 2d), suggesting that
they exert selectively toxic effects on bacterial membranes. We
focused our subsequent studies on celastrol and NDGA, since
the selectivity of these redox-active compounds for bacterial
membranes and their ability to eradicate staphylococcal biofilms
suggested the greatest potential for therapeutic utility.
Mechanistic basis for antibiofilm activity of redox-active
compounds
Since all of the redox-active compounds displayed antibacterial
activity against planktonic cells, we sought to examine why some
of these agents were able to eradicate staphylococcal biofilms
(‘eradicators’), whilst others were not (‘non-eradicators’). We stud-
ied a representative compound of each class (the eradicator celas-
trol and the non-eradicator 8-hydroxyquinoline) and examined
whether lack of antibiofilm activity was due to a failure of com-
pounds to penetrate the biofilm.42 The non-eradicator
8-hydroxyquinoline showed more extensive biofilm penetration
(105+2%) than the eradicator celastrol (44+4%). Therefore, fail-
ure of compounds to penetrate the biofilm does not appear to
underlie the lack of activity of the non-eradicators against biofilms.
The failure of most established antibacterial drugs to eradicate
bacterial biofilms has been attributed to the inability of these
compounds to effectively kill the large population of slow- or non-
growing (SONG) bacteria, including persister cells, present in bio-
films.43 To assess whether redox-active compounds capable of
biofilm eradication do so because they retain bactericidal activity
against SONG cells, we examined their ability to kill stationary-
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Figure 1. Evaluation of the bactericidal activity of redox-active compounds at 4×MIC for S. aureus SH1000. T0 represents the number of cells present in
cultures prior to addition of compounds. Results are means of at least three independent replicates and error bars show standard deviations.
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phase and persister cells in planktonic culture. Neither celastrol
nor NDGA showed significantly enhanced killing of SONG cells
compared with compounds lacking antibiofilm activity (daptomy-
cin and 8-hydroxyquinoline) (Figure 3).
We subsequently examined whether biofilm-eradicating redox-
active compounds might act by causing physical perturbation of
the biofilm. Biofilm matrix material and cells were quantified
following exposure to compounds for 24 h to identify whether
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Figure 2. Effect of redox-active compounds and comparator agents at 4×MIC on bacterial andmammalianmembranes. Bacterial membrane integrity
was measured using the BacLightTM assay (a) and bymonitoring leakage of intracellular potassium (b). Bacterial membrane potential wasmeasured by
leakage of DiSC3(5) (c). Mammalian membrane integrity was measured by leakage of haemoglobin from erythrocytes (d). Filled bars show comparator
agents. Results are means of at least three independent determinations and error bars show standard deviations.
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compound-induced alterations in biofilm structure distinguished
biofilm eradicators from non-eradicators. At 256 mg/L, eradicators
significantly reduced the amount of adherent matrix and cells in
comparison with non-eradicators (Figure 4a and b). To investigate
whether this was a cause or a result of eradicator-mediated per-
turbation of the biofilm, viable cells and adherent matrix material
were quantified following exposure to NDGA and celastrol for a
shorter time period (1 h). Over this time period, the compounds
had little or no effect on total cell viability (both released and
attached cells) (Figure 4c), while adherent material was signifi-
cantly reduced (Figure 4d and e), implying that biofilm detachment
is not simply a consequence of cell death. Therefore, celastrol and
NDGA appear to exert their antibiofilm effects at least in part by
inducing destructuring of the biofilm.
Preliminary evaluation of the potential for use of celastrol
and NDGA as topical antistaphylococcal agents
For a compound to be developed as a topical antibiofilm agent, it
should not cause damage or irritation to the skin upon applica-
tion. NDGA and celastrol have previously shown no notable
adverse effects on human or mouse skin by visual inspection
when investigated as topical preparations at 300 mg/L for the
treatment of psoriasis and 500 mg/L for reducing inflammation,
respectively.44,45 Therefore, whilst some evaluation of toxicity
has been conducted with both celastrol and NDGA, the possibility
that these compounds could trigger irritation and/or physical
damage to human skin has not been examined in detail.
To determine whether celastrol and NDGA exhibit sufficient
selective toxicity to allow their topical use on human skin, we
examined their effects upon a human living skin equivalent
model (LabSkinTM). In vitro, three-dimensional skin models such
as this represent an established means of evaluating the acute
dermal toxicity of test compounds.22,46Following 24 h of exposure
to either celastrol or mupirocin (control) at 10× S. aureus SH1000
MIC (10 and 1.25 mg/L, respectively) we detected no increase in
release of the inflammatorymarker IL-1a, an indicator of irritation
(data not shown).47 The limited solubility of NDGA meant that, in
order to keep the solvent load below the level (0.5%) causing
damage to LabSkinTM, the compound could only be tested at a
concentration equivalent to 4× S. aureus SH1000 MIC (256 mg/L).
However, no increase in IL-1a release was detected at this
concentration. Haematoxylin/eosin staining of tissue sections fol-
lowing 24 h of exposure tomupirocin, celastrol and NDGA showed
no visible detrimental effects on skin (Figure 5d–f). By contrast,
exposure of LabSkinTM to the known irritant SDS induced a
30-fold increase in release of IL-1a (data not shown) and was
severely damaging to the skin structure, causing shedding of
the top layers of skin (stratum corneum and epidermis) and injury
to the dermis (Figure 5c). Thus, celastrol and NDGA did not cause
irritation or damage to fully differentiated skin at concentrations
above those required to inhibit growth of bacterial cultures.
A desirable feature of any potential antibacterial agent for clin-
ical use is a low propensity to select resistance. The resistance
potential for NDGA and celastrol was initially evaluated by plating
saturated cultures of S. aureus SH1000 onto agar containing these
compounds at 4×MIC. In neither casewere resistantmutants iso-
lated (mutation frequency ,5.0×1029). This suggested that the
redox-active compounds have low resistance potentials and
that multiple mutations may be required to develop resistance
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Figure 3. Viability of S. aureus SH1000 slow-growing and persister cells
following exposure to compounds for 24 h. (a) Exponential- and stationary-
phase cell viability following exposure to biofilm eradicators at the MBEC or
biofilm non-eradicators at 256 mg/L. T0 is the culture density before the
addition of compounds. (b) Cell viability of ciprofloxacin and ampicillin
persisters following exposure to compounds at 10× MIC. Results are
means of at least three independent determinations and error bars show
standard deviations.
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Figure 4. Cell viability and quantification of adherentmaterial by fluorescent staining following exposure of biofilms to compounds at 256 mg/L for 24 h
or 60 min. (a) Attached matrix (24 h). (b) Attached cells (24 h). (c) Total biofilm cell viability (60 min). (d) Attached matrix (60 min). (e) Attached cells
(60 min). The data labelled T0 show the quantity of matrix and cells before the addition of compounds and RFU denotes relative fluorescence units.
Results are means of at least three independent determinations, with error bars showing standard deviations.
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to the agents.48 To examine whether resistance might arise fol-
lowing prolonged selection, we employed the extended gradient
MIC method,23 using an established antibacterial agent with
a low resistance potential (daptomycin) as a comparator.24
Resistance (defined for the purpose of this experiment as a
≥4-fold increase in MIC) to daptomycin arose in eight independent
selection cultures of S. aureus SH1000 after 10 passages and the
most resistant strain recovered displayed a 16-fold reduction
in daptomycin susceptibility following 40 passages (Figure 6).
Celastrol resistance arose over the same time-scale as daptomycin
resistance (10 passages) in all selection cultures and the most
resistant strain exhibited an8-fold reduction in celastrol susceptibil-
ity after 40 passages (Figure 6). No reduction in NDGA susceptibility
was observed in S. aureus SH1000 after 40 passages in the pres-
ence of the compound (data not shown). Thus, both celastrol
and NDGA have low resistance potential, implying that resistance
would be unlikely to arise rapidly should these compounds be
used in the clinical setting for topical treatment of staphylococcal
infection.
Previous studies with a subset of the agents under investigation
here have reported compound-mediated potentiation of the anti-
staphylococcal activity of established antibacterial drugs. Thus,
dihydroxychalcone showed synergism with doxycycline, gentami-
cin and ciprofloxacin,49 and totarol increased the activity of
b-lactams against S. aureus.34 Therefore, we investigated the pos-
sibility that celastrol and NDGA might exhibit synergistic effects in
biofilm eradication assays when combined with licensed antibac-
terial drugs (tetracycline, ciprofloxacin, erythromycin, gentamicin
and oxacillin). Celastrol and NDGA both exhibited synergywith gen-
tamicin against S. aureus SH1000 biofilms (FIC index ≤0.25 and
≤0.15, respectively), an antibiotic that was alone unable to eradi-
cate biofilms at the concentrations tested (≤256 mg/L), whilst all
the other compound–antibacterial drug combinations showed
additive effects (FIC index.0.5). Aminoglycosides are often applied
as a topical cream at 0.1% (1 g/L) for the sterilization of infected
wounds,50 but this concentration of gentamicin is insufficient to
eradicate established staphylococcal biofilms, at least in vitro
(data not shown). We therefore investigated the concentrations
(a) (b)
(f)(e)
(d)(c)
Stratum corneum
Epidermis
Dermis
Figure 5. Haematoxylin/eosin-stained sections of LabSkinTM exposed to compounds for 24 h. (a) Untreated control. (b) Solvent (0.2% ethanol, v/v).
(c) SDS (5%, w/v). (d) Mupirocin at 10×MIC (0.000125%, w/v). (e) Celastrol at 10×MIC (0.001%, w/v). (f) NDGA at 4×MIC (0.0256%, w/v).
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of celastrol or NDGA that would need to be administered alongside
0.1% gentamicin to eradicate preformed staphylococcal biofilms
in vitro. Eradication of S. aureus SH1000 biofilms by 0.1%gentamicin
was achieved in conjunction with 0.004 mg/L celastrol or 0.25 mg/L
NDGA. Our results suggest that the combination of gentamicin with
low concentrations of these redox-active compounds could poten-
tially be employed topically to more effectively treat superficial
staphylococcal infections that involve a biofilm component.
Conclusions
We have characterized a number of redox-active compounds that,
in addition to demonstrating antistaphylococcal activity, are cap-
able of eradicating established staphylococcal biofilms. A subset
of these compounds shows a degree of prokaryotic selectivity.
The antibacterial action of these compounds ismediated bymem-
brane perturbation, whilst the antibiofilm MOA appears to involve
disruption of the biofilmmatrix. Neither celastrol nor NDGA caused
irritation or damage to the skin surface in a living skin equivalent
model. Therefore, these compounds deserve further consideration
as potential antibiofilm agents for topical application, either alone
or in a synergistic combination with aminoglycosides. The low
resistance potential of both celastrol and NDGA suggests that
their use as topical antibiofilm treatments would not rapidly
become compromised by the development of resistance.
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